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Improved HIV and Substance Abuse Treatment
Outcomes for Released HIV-Infected Prisoners:
The Impact of Buprenorphine Treatment
Sandra Ann Springer, Shu Chen, and Frederick L. Altice
ABSTRACT HIV-infected prisoners fare poorly after release. Though rarely available,
opioid agonist therapy (OAT) may be one way to improve HIV and substance abuse
treatment outcomes after release. Of the 69 HIV-infected prisoners enrolled in a
randomized controlled trial of directly administered antiretroviral therapy, 48 (70%)
met DSM-IV criteria for opioid dependence. Of these, 30 (62.5%) selected OAT, either
as methadone (N=7, 14.5%) or buprenorphine/naloxone (BPN/NLX; N=23, 48.0%).
Twelve-week HIVand substance abuse treatment outcomes are reported as a sub-study
for those selecting BPN/NLX. Retention was high: 21 (91%) completed BPN/NLX
induction and 17 (74%) remained on BPN/NLX after 12 weeks. Compared with
baseline, the proportion with a non-detectable viral load (61% vs 63% log10 copies/
mL) and mean CD4 count (367 vs 344 cells/mL) was unchanged at 12 weeks. Opiate-
negative urine testing remained 83% for the 21 who completed induction. Using means
from 10-point Likert scales, opioid craving was reduced from 6.0 to 1.8 within 3 days
of BPN/NLX induction and satisfaction remained high at 9.5 throughout the 12 weeks.
Adverse events were few and mild. BPN/NLX therapy was acceptable, safe and
effective for both HIV and opioid treatment outcomes among released HIV-infected
prisoners. Future randomized controlled trials are needed to affirm its benefit in this
highly vulnerable population.
KEYWORDS Buprenorphine, Substance abuse, Opioid dependence, HIV, AIDS,
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INTRODUCTION
In the USA, the prevalence of HIV among prisoners is approximately three times
greater than in surrounding communities.
1 Indeed, 14% of all people living with
HIV encounter the criminal justice system annually.
2 As such, prisons are an
important place to detect HIV, treat it, and serve as a conduit to care after release.
The availability of highly active antiretroviral therapy has transformed HIV into a
chronically manageable condition, even for prisoners.
3,4 Unfortunately for prison-
ers, including those with HIV, the 3-month period after release is a highly vulnerable
time period, resulting in high rates of recidivism to prison,
5 relapse to drug use,
6–8
and overdose resulting in death.
9 For those with HIV, decreased access to
antiretroviral therapy,
10 poor virological and immunological treatment out-
comes,
11,12 and high rates of HIV risk behaviors have been conﬁrmed.
13 Thus,
researchers, practitioners, and policy makers have emphasized that the ﬁrst 3 months
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592after release to the community is a crucial period for newly released prisoners. If
successful reintegration is not achieved during this period, it is not likely to
occur.
14–16
These ﬁndings create an urgent need to adapt and test evidence-based transitional
interventions for this population. Opioid agonist therapy (OAT), including methadone
and buprenorphine/naloxone (BPN/NLX) therapy, decrease heroin use, time to relapse,
criminal activity and HIV risk behaviors and increase retention in treatment and are
cost-effective to society.
17,18 Moreover, 85–90% of inmates with histories of opioid
dependence relapse to heroin use within one year after release,
6,7 yet OAT is rarely
available.
19–21 For unclear reasons, the criminal justice system has not adopted these
effective treatments, particularly for those with HIV who might beneﬁtm o s t .
22
We therefore sought to establish acceptability, feasibility, and early HIV and
substance abuse treatment outcomes after introducing BPN/NLX at the time of
release from prison in HIV-infected patients receiving antiretroviral therapy. BPN/
NLX, unlike methadone that is a full opioid mu-agonist, is a partial mu-agonist and
was selected for its favorable safety proﬁle, reduced likelihood for overdose and
death and few pharmacokinetic drug interactions with antiretroviral medications.
23
METHODS
Recruitment All subjects were recruited from within a randomized controlled trial of
directly administered antiretroviral therapy (DAART) among HIV-infected prisoners
transitioning to the community within 90 days. Those who met DSM-IV criteria for
opioid-dependence were assessed for interest in OAT with either methadone or BPN/
NLX. Additional eligibility criteria included: (1) returning to either New Haven or
Hartford; (2) age ≥ 18 years; (3) a negative urine pregnancy test for women and
willingness to use contraception; and (4) expressing an interest in BPN/NLX
treatment. As part of the ongoing parent study, subjects were randomized 2:1 to
receive DAART versus self-administered therapy (SAT).
Study Procedures Within 90 days before community-release, all subjects underwent
informed consent, baseline assessments and chart review. Assessments included
demographic information, mental illness and chemical dependence screening using
the Mini-International Neuropsychiatric Interview (M.I.N.I),
24 Addiction Severity
Index,
25,26 and Alcohol Use Disorders Identiﬁcation Test.
27 Alcohol and drug use
questions referred to the pre-incarceration period to establish historical diagnoses, as
no subject was actively using drugs or alcohol. Subjects underwent secondary
consent procedures after release to avoid any perceived or real coercion. Additional
post-release activities included baseline physical exam and weekly assessment of
opiate craving (10-point Likert-scale), buprenorphine satisfaction (10-point Likert-
scale), urine toxicology screening using the NIDA-6 (opiates, cocaine, methadone,
benzodiazepines, marijuana, and methamphetamines), and separate urine tests for
oxycodone and buprenorphine (Redwood Biotech, Santa Rosa, CA). Baseline and
quarterly HIV-1 RNA levels (Amplicor 1.5; Roche) and CD4 lymphocyte counts
(FACS; Quest) were obtained.
Buprenorphine Induction Process BPN/NLX induction was allowed up to 30 days
post-release from prison; however, the day of release was targeted when possible.
Due to low expected tolerance to opioids, subjects were initially administered
THE IMPACT OF BUPRENORPHINE FOR HIV-INFECTED PRISONERS 5932.0 mg/0.5 mg BPN/NLX and increased by 2 mg/0.5 mg increments of BPN/NLX, as
tolerated, to reduce the craving score to 1, while avoiding opiate agonist side effects.
BPN/NLX dose, craving for opiates, opioid withdrawal symptoms, opioid-agonist
side effects, and urine drug screening were all collected daily during the induction
and weekly thereafter. All subjects received weekly, standardized, and manual-based
counseling per protocol
28 for 45–60 min by a certiﬁed substance abuse treatment
counselor. Study personnel linked counseling visits to collection of urine screens.
Buprenorphine Administration For those randomized to DAART, BPN/NLX was
observed daily along with their antiretroviral therapy and other chronically
prescribed medications. BPN/NLX dispensing, similar to the SAT group, was
contingent upon attending weekly counseling sessions. For those in the SAT arm,
BPN/NLX was contingent upon attending weekly counseling sessions where a
voucher was provided to allow the pharmacy to release the BPN/NLX. Counselors
provided a 7-day prescription voucher after providing a urine specimen and
attending weekly counseling sessions. The voucher was not contingent on urine
specimen results.
Follow-up Subjects were evaluated daily by the study clinician during the induction
phase and at least monthly thereafter. Counselors met with subjects weekly,
irrespective of study assignment, and assessed urine toxicology screening, opiate
craving, BPN/NLX satisfaction, and adverse side effects. Structured interviews and
phlebotomy for CD4 lymphocyte count and HIV-1 RNA level were conducted at
weeks 4 and 12.
Analytic Strategy Outcomes from the ﬁrst 12 weeks are reported for the ﬁrst 23
subjects recruited. The primary HIV treatment outcome was the proportion with a
non-detectable HIV-1 RNA level 12 weeks after prison-release since this is the most
vulnerable time period. CD4 counts are similarly reported. The primary substance
abuse treatment outcome was retention in BPN/NLX treatment. Secondary drug
treatment outcomes included the percentage of opioid-free urine toxicology results
over 12 weeks. Missing urine results were adjudicated in the following sequential
manner: (1) self-report at weekly visits; and (2) last value carried forward only if a
single missing value was noted; (3) for subjects who remained in the trial, missing
consecutive urine values were considered positive. Therefore, the proportion of
positive urine tests was calculated as the percent positive out of the number who
remained in the trial for each week and included missing value adjudication.
Craving and satisfaction scores were calculated as the mean for those individuals
whose results were reported weekly.
Institutional Review Boards at both Yale University and the University of
Connecticut and the Research Committee at the Connecticut Department of
Correction approved the study; a Certiﬁcate of Conﬁdentiality was also obtained.
The parent study is registered at www.clinicaltrials.gov (NCT00786396).
RESULTS
Figure 1 depicts the disposition of the 69 subjects enrolled in the parent study; 70%
(N=48) met DSM-IV criteria for opioid dependence. Of these, 14.5% (N=7) chose
methadone, 37.5% (N=18) chose no form of OAT, and 48% (N=23) chose to be
inducted on BPN/NLX.
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buprenorphine treatment. The 2:1 randomization of the parent study resulted in 16
receiving BPN/NLX as DAART and seven self-administering it. All subjects (N=23)
had at least one Axis I disorder: 52% had thought disorders (i.e. schizophrenia and
psychosis) and 78% had mood disorders (i.e. major depression, and bipolar
disorder). The majority (61% of 23) with Axis I anxiety disorders (i.e. Post-
Traumatic Stress Disorder, General Anxiety Disorder, Obsessive Compulsive
Disorder) was also prescribed psychiatric medications.
For the primary HIV treatment outcome (see Figure 2), the proportion of subjects
with a non-detectable HIV-1 RNA levels at 12 weeks did not differ from baseline
(61% vs. 63%, p=0.91). The mean CD4 lymphocyte count (367 vs. 344, p=0.89) did
not differ statistically either. For those subjects whose HIV-1 RNA level was
FIGURE 1. Subject allocation.
TABLE 1 Baseline characteristic of study participants (N=23)
Characteristic
Mean age (years) 46.4
Gender (M/F), N (%) 18 (78):5 (22)
Race/ethnicity
Black, N (%) 9 (39)
Hispanic, N (%) 12 (52)
White, N (%) 2 (9)
Co-morbid axis I mental disorders
a 23 (100)
Thought disorders, N (%) 12 (52)
Mood disorders, N (%) 18(78)
Anxiety disorders, N (%) 14(61)
Prior opioid agonist treatment
Methadone, N (%) 19 (82.6)
BPN/NLX, N (%) 5 (21.7)
Methadone and BPN/NLX, N (%) 5 (21.7)
Randomization (DAART/SAT) 16:7
Median months of incarceration (IQ range) 7 (5–11)
Baseline AUDIT score 6.78 (±7.71)
Mean baseline CD4+ lymphocytes (cells/mL) 344 (±222)
HIV-1 RNAG50 (%) 63
Mean HIV-1 RNA (among VL950, copies/mL) 4.11 log10
aM.I.N.I prison diagnosis and/or psychiatric medications
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log10 copies/mL).
Among the 23 subjects initiating BPN/NLX, 91% (N=21) completed the
induction period. Two subjects left the study after a single dose of BPN/NLX and
were subsequently lost to follow-up to both the BPN/NLX and the parent study. After
induction, the mean daily BPN/NLX dose at which subjects were stabilized was
9.5 mg (range, 2 to 16 mg). There were no differences between the mean BPN/NLX
dose for those treated and not treated with atazanavir-containing regimens (9.20 mg
vs. 8.46 mg; p=0.82), yet there was a trend toward higher BPN/NLX dosage when co-
administered with efavirenz-containing regimens (10.33 mg vs. 5.33 mg; p=0.10).
Compared to baseline, mean opioid craving scores decreased from 6 to 1.8 after
induction completion (on average, 3 days) and remained 2.2 by the end of 12 weeks.
The mean satisfaction with BPN/NLX treatment score was high at 9.5 throughout
the 12-week period (see Figure 3) for the 17 retained subjects. Overall, retention was
high at 12 weeks—74% for all 23 subjects and 81% for the 21 who completed
induction. One successfully inducted subject withdrew from BPN/NLX because she
required a prescribed narcotic for a pain-related syndrome; two were reincarcerated
FIGURE 2. HIV treatment outcomes.
FIGURE 3. Opiate craving and satisfaction with buprenorphine treatment.
SPRINGER ET AL. 596after cocaine-relapse (opiate screens remained negative); and one withdrew due to
nausea, a side effect he attributed to BPN/NLX.
Figure 4 depicts the urine toxicology results for buprenorphine, other opioids and
cocaine overthe 12-weekperiod.Urineopiate positivitydecreasedfrom 29%atbaseline
to 17% at the end of 12 weeks for the 17 subjects who completed 12 weeks; it was 20%
for the 21 subjects who completed the 3-day induction. Similarly urine cocaine positivity
ranged from 43% at baseline to 29% at 12 weeks. Receiving HIV and BPN/NLX
medications as DAART vs. SAT did not signiﬁcantly differ for retention between groups
(72.2% vs 92.9%, p=0.17), but the study was underpowered to detect a difference.
The mean number of days between release from prison and receiving the ﬁrst
induction dose of BPN was 8.5 (range 0 to 30 days). The delay between release and
starting buprenorphine resulted in positive urine testing at baseline. Comparing the
14 subjects who were inducted “early” (within the ﬁrst 7 days of release), versus the
nine inducted “later” (after 7 days of release), there was no statistical difference in
the mean retention on treatment (11.0 vs. 10.6 weeks, p=0.79), the proportion
completing all 12 weeks (84.6% vs. 87.5%, p=1.00), the percent of negative urine
screens for opiates (70% vs. 86%, p=0.47)and cocaine (51.0 vs. 70.6%, p=0.56),
and the mean BPN dose at the completion of induction (9.8 vs. 8.9 mg, p=0.31).
Adverse side effects, including constipation, headache, nausea and drowsiness
from BPN/NLX during the 12 weeks of the study were considered mild and easily
addressed by the treatment team. The one subject who withdrew from the BPN/
NLX treatment for nausea refused treatment with anti-emetics. No subject
experienced opioid withdrawal symptoms or overdose during the 12-week study
period. Side effects were not associated with co-administration of atazanavir or
efavirenz (data not shown).
DISCUSSION
Though small, this pilot feasibility study has important implications for both clinical
careandresearch.First,itistheﬁrststudytodemonstratethatHIVtreatmentoutcomes
persist during transition from prison and there were few adverse consequences. Second,
FIGURE 4. Percent of positive urine toxicology tests over time.
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prevention for opioid-dependent, HIV-infected prisoners transitioning to the commun-
ity. Last, this study demonstrates not only a high preference for BPN/NLX over
methadone or no OAT among those with opioid dependence, but demonstrates high
levels of acceptability and satisfaction.
Prison-release studies of HIV-infected patients, including those from Connect-
icut, conﬁrm poor virological and immunological outcomes within 12 weeks of
release.
11,12 While case management interventions have successfully linked released
prisoners to care, none have conﬁrmed stability in HIV treatment outcomes. Recent
data from Texas suggest that reﬁlling prescriptions is low among released HIV-
infected prisoners,
10 but this obstacle was not present in this study since all
prescriptions were continued for all study subjects. The Texas study, however, did
not assess the reasons for not ﬁlling prescriptions, which might have resulted from
relapse to drug use. Though these pilot data are not powered sufﬁciently to
determine if BPN/NLX treatment alone led to these successful clinical endpoints,
these data remain compelling and suggest that BPN/NLX was an important factor in
stabilizing the lives of subjects, resulting in improved adherence to antiretroviral
therapy. Though insufﬁciently powered, it is now necessary to recruit larger sample
sizes to determine if DAART plays a role in retention and outcomes. Ultimately,
buprenorphine treatment alone without DAART needs evaluation through the rigors
of a randomized controlled trial to determine its effectiveness.
Similar to most correctional settings in the Northeast where HIV prevalence
rates are highest, the majority (70%) of all released HIV-infected prisoners on
antiretroviral therapy met DSM-IV criteria for opioid dependence. Not only did the
majority of those with opioid dependence choose OAT over no pharmacological
therapy, but also BPN/NLX was preferred over methadone. Though numerous
explanations may be posited, the greater preference for BPN/NLX may reﬂect
previous negative experiences with or perceptions about methadone among this
population;
29 this ﬁnding is supported by the near universal (980%) prior
experience with methadone treatment (see Table 1). One of the misconceptions by
prisoners who are no longer using illicit drugs is that “OAT would no longer be
needed” after prolonged periods of forced abstinence. Absent from that perspective,
however, is the recognition that opioid-relapse is high and approaches 85–90%
6
even after prolonged imprisonment.
Though the sample size was small, BPN/NLX was feasible and efﬁcacious.
There are no other studies of BPN/NLX treatment for HIV-infected released
prisoners, but compared with HIV-undifferentiated released prisoners, substance
abuse outcomes are similar to other studies. Among opioid-dependent prisoners in
Baltimore with unknown HIV status, the use of methadone resulted in retention,
efﬁcacy and urine toxicology results similar to ours three months after release.
6,30
We extended their ﬁndings to HIV-infected subjects receiving antiretroviral therapy
and demonstrated sustained HIV treatment response, high retention rates (970%),
low opiate- (17%) and cocaine-positive (29%) urine tests, and no associated adverse
consequences between buprenorphine and HIV therapeutics. The retention rate of
74% (N=17/23), although potentially affected by the DAART intervention itself in
this study, is higher than described in smaller studies of BPN/NLX treatment of HIV-
infected persons in the USA
31 and prisoners in Puerto Rico.
32 This study also
conﬁrms ﬁndings reported from other small studies that have shown that BPN/NLX
can be prescribed safely and effectively in HIV primary care settings;
31,33 HIV-
undifferentiated prisoners in Puerto Rico;
32 and France.
5,34,35
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release from prison, accounting for the high proportion of positive urine results at
baseline. To avoid early relapse and potential overdose and death, relapse
prevention strategies should be initiated prior to release from prison. This is
particularly true since opioid tolerance is low and risk for overdose and death is
high.
9 Future studies should focus on initiating treatment prior to release.
In this study of opioid dependent subjects with prolonged periods of abstinence,
BPN/NLX treatment was well tolerated, but required an extended induction period
over 7 days. Dosing started lower than recommended by existing guidelines for
chronic opioid-using patients,
36 and increases in dosage was slow and incremental.
Fortunately, excess opioid-agonist effects were infrequent (17%) during the
induction period (i.e., drowsiness, nausea, headache, constipation), extinguished
by the end of the induction period. Induction did, however, require longer duration
of induction due to the down-regulation of opioid receptors after prolonged periods
of abstinence and potentially from known symptomatic pharmacokinetic interac-
tions with ritonavir-boosted atazanavir.
37 Overall, tolerability remained high despite
potential pharmacokinetic drug interactions reported between BPN/NLX and
antiretroviral medications.
23,37,38
Last, this study represents a population of HIV-infected individuals who often
have many unmet needs and co-morbidities, and who might not otherwise receive
such treatment. The unexpected universal co-occurrence of mental illness (100% of
subjects with documented Axis I disorders) suggests a particularly challenging
population to treat. Indeed, collectively all subjects met criteria for triple diagnosis
and their management has traditionally been fraught with multiple challenges.
39,40
Left untreated, mental illness and substance use disorders contribute signiﬁcantly to
difﬁculty with maintaining appointments with medical professionals and often are
associated with reincarceration.
4,41,42 When effective support is offered, however,
they can maintain clinical beneﬁt from treatment.
43
BPN/NLX may offer added incentives to correctional settings that might result
in increased use of OAT. These include decreased: (1) regulatory procedures and
licensing; (2) concerns about diversion and overdose; and (3) concerns about opioid
withdrawal symptoms if a subject is not effectively and immediately linked to
community services.
22 One of the major barriers to BPN/NLX treatment has been
the actual cost of the medication, although it has been found to be similarly cost-
effective as methadone.
44 This concern, however, may be obviated as the BPN/NLX
patent ended in late 2009, potentially allowing for less expensive generics to emerge.
CONCLUSION
Buprenorphine induction and stabilization is a highly acceptable, tolerable and
effective treatment to prevent relapse to opiate use in released HIV-infected
prisoners. Importantly, it appears to be effective at maintaining HIV outcomes and
potentially decreasing HIV-associated morbidity and mortality. This study initiated
BPN/NLX after release from prison, but future studies, including randomized trials
examining BPN/NLX induction before and after release are needed to determine the
optimal timing for treatment. More importantly, better understanding of the impact
that BPN/NLX treatment may have on recidivism, continuity of HIV care, ART
adherence and HIV mortality through larger randomized controlled trials are
urgently needed.
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